BR112022013843A2 - Método de diferenciação de células neurais e composições relacionadas e métodos de uso - Google Patents
Método de diferenciação de células neurais e composições relacionadas e métodos de usoInfo
- Publication number
- BR112022013843A2 BR112022013843A2 BR112022013843A BR112022013843A BR112022013843A2 BR 112022013843 A2 BR112022013843 A2 BR 112022013843A2 BR 112022013843 A BR112022013843 A BR 112022013843A BR 112022013843 A BR112022013843 A BR 112022013843A BR 112022013843 A2 BR112022013843 A2 BR 112022013843A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- differentiation
- related compositions
- neural cells
- cells
- Prior art date
Links
- 230000004069 differentiation Effects 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000001537 neural effect Effects 0.000 title abstract 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 2
- 210000002569 neuron Anatomy 0.000 abstract 2
- 210000000130 stem cell Anatomy 0.000 abstract 2
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 229960003638 dopamine Drugs 0.000 abstract 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 abstract 1
- 210000001259 mesencephalon Anatomy 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 210000001778 pluripotent stem cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0619—Neurons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0062—General methods for three-dimensional culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/41—Hedgehog proteins; Cyclopamine (inhibitor)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases [EC 2.]
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062960669P | 2020-01-13 | 2020-01-13 | |
| PCT/US2021/013324 WO2021146349A1 (en) | 2020-01-13 | 2021-01-13 | Method of differentiating neural cells and related compositions and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022013843A2 true BR112022013843A2 (pt) | 2022-09-13 |
Family
ID=74557262
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022013843A BR112022013843A2 (pt) | 2020-01-13 | 2021-01-13 | Método de diferenciação de células neurais e composições relacionadas e métodos de uso |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230059010A1 (https=) |
| EP (1) | EP4090734B1 (https=) |
| JP (2) | JP7669048B2 (https=) |
| CN (2) | CN119432744A (https=) |
| AU (2) | AU2021209068B2 (https=) |
| BR (1) | BR112022013843A2 (https=) |
| CA (1) | CA3167713A1 (https=) |
| ES (1) | ES3008210T3 (https=) |
| IL (1) | IL294565B2 (https=) |
| MX (1) | MX2022008625A (https=) |
| SA (1) | SA522433282B1 (https=) |
| WO (1) | WO2021146349A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023004366A1 (en) * | 2021-07-21 | 2023-01-26 | Aspen Neuroscience, Inc. | Transposon-based modulation of gba1 and related compositions and uses thereof |
| WO2023004370A1 (en) * | 2021-07-21 | 2023-01-26 | Aspen Neuroscience, Inc. | Aav-based modulation of gba1 and related compositions and uses thereof |
| WO2023137200A2 (en) * | 2022-01-13 | 2023-07-20 | The Board Of Trustees Of The Leland Stanford Junior University | Generation of neural organizer organoids and midline assembloids from human pluripotent stem cells |
| JP2025512359A (ja) * | 2022-04-11 | 2025-04-17 | リサーチ ディベロップメント ファウンデーション | 分化した神経細胞を作出および使用するための方法 |
| WO2023201361A1 (en) | 2022-04-15 | 2023-10-19 | Aspen Neuroscience, Inc. | Methods of classifying the differentiation state of cells and related compositions of differentiated cells |
| US12565639B2 (en) | 2023-06-13 | 2026-03-03 | Aspen Neuroscience, Inc. | Methods for differentiating dopaminergic neurons from stem cells |
| US20250157580A1 (en) | 2023-11-13 | 2025-05-15 | Aspen Neuroscience, Inc. | Methods of predicting dopamine production capability of differentiated neuronal cells |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| US5925517A (en) | 1993-11-12 | 1999-07-20 | The Public Health Research Institute Of The City Of New York, Inc. | Detectably labeled dual conformation oligonucleotide probes, assays and kits |
| US5538848A (en) | 1994-11-16 | 1996-07-23 | Applied Biosystems Division, Perkin-Elmer Corp. | Method for detecting nucleic acid amplification using self-quenching fluorescence probe |
| SE506700C2 (sv) | 1996-05-31 | 1998-02-02 | Mikael Kubista | Sond och förfaranden för analys av nukleinsyra |
| JP4540754B2 (ja) | 1996-06-04 | 2010-09-08 | ユニバーシティ オブ ユタ リサーチ ファウンデーション | Ｐｃｒ中のハイブリダイゼーションのモニタリング |
| GB9812768D0 (en) | 1998-06-13 | 1998-08-12 | Zeneca Ltd | Methods |
| WO2002014555A2 (en) | 2000-08-11 | 2002-02-21 | University Of Utah Research Foundation | Single-labeled oligonucleotide probes |
| ITCZ20020002A1 (it) | 2002-04-11 | 2003-10-13 | Parco Scient E Tecnologico Del | Dispositivo e metodo per il rilevamento simultaneo di differenti anticorpi e antigeni in campioni clinici, alimentari ed ambientali |
| WO2013163228A1 (en) * | 2012-04-24 | 2013-10-31 | International Stem Cell Corporation | Derivation of neural stem cells and dopaminergic neurons from human pluripotent stem cells |
| WO2013187416A1 (ja) * | 2012-06-12 | 2013-12-19 | 学校法人 慶應義塾 | 神経系分化に適したiPS細胞の増幅方法、及び神経幹細胞の誘導方法 |
| AU2014316100B2 (en) * | 2013-09-05 | 2020-11-05 | Eisai R&D Management Co., Ltd. | New method for inducing dopamine-producing neural precursor cells |
| AU2014352773B2 (en) * | 2013-11-21 | 2021-04-29 | Memorial Sloan-Kettering Cancer Center | Specification of functional cranial placode derivatives from human pluripotent stem cells |
| ES2939807T3 (es) * | 2014-03-21 | 2023-04-27 | Fujifilm Cellular Dynamics Inc | Producción de neuronas dopaminérgicas del mesencéfalo y métodos para su utilización |
| WO2017160234A1 (en) * | 2016-03-14 | 2017-09-21 | Agency For Science, Technology And Research | Generation of midbrain-specific organoids from human pluripotent stem cells |
| JP7011260B2 (ja) * | 2016-04-22 | 2022-02-10 | 国立大学法人京都大学 | ドーパミン産生神経前駆細胞の製造方法 |
| US20210123017A1 (en) * | 2017-04-19 | 2021-04-29 | National University Corporation Nagoya University | Method for producing dopaminergic neurons |
| EP3715450A4 (en) * | 2017-11-24 | 2021-08-25 | Sumitomo Chemical Company, Limited | METHOD OF PREPARING CELL MASS, INCLUDING HYPOPHYSICAL TISSUE, AND CELL MASS THEREOF |
| ES2968737T3 (es) * | 2018-11-06 | 2024-05-13 | Juno Therapeutics Inc | Proceso para producir células T manipuladas genéticamente |
-
2021
- 2021-01-13 AU AU2021209068A patent/AU2021209068B2/en active Active
- 2021-01-13 ES ES21703795T patent/ES3008210T3/es active Active
- 2021-01-13 BR BR112022013843A patent/BR112022013843A2/pt unknown
- 2021-01-13 IL IL294565A patent/IL294565B2/en unknown
- 2021-01-13 US US17/792,632 patent/US20230059010A1/en active Pending
- 2021-01-13 CN CN202411614157.3A patent/CN119432744A/zh active Pending
- 2021-01-13 MX MX2022008625A patent/MX2022008625A/es unknown
- 2021-01-13 CN CN202180020647.9A patent/CN115335511A/zh active Pending
- 2021-01-13 EP EP21703795.1A patent/EP4090734B1/en active Active
- 2021-01-13 JP JP2022542668A patent/JP7669048B2/ja active Active
- 2021-01-13 CA CA3167713A patent/CA3167713A1/en active Pending
- 2021-01-13 WO PCT/US2021/013324 patent/WO2021146349A1/en not_active Ceased
-
2022
- 2022-07-12 SA SA522433282A patent/SA522433282B1/ar unknown
-
2024
- 2024-12-19 AU AU2024278587A patent/AU2024278587A1/en active Pending
-
2025
- 2025-04-09 JP JP2025064082A patent/JP2025118628A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022008625A (es) | 2022-09-09 |
| EP4090734B1 (en) | 2024-11-06 |
| AU2021209068A1 (en) | 2022-07-28 |
| CA3167713A1 (en) | 2021-07-22 |
| JP2025118628A (ja) | 2025-08-13 |
| IL294565A (en) | 2022-09-01 |
| EP4090734C0 (en) | 2024-11-06 |
| CN115335511A (zh) | 2022-11-11 |
| EP4090734A1 (en) | 2022-11-23 |
| JP2023512453A (ja) | 2023-03-27 |
| IL294565B2 (en) | 2025-04-01 |
| AU2024278587A1 (en) | 2025-01-16 |
| IL294565B1 (en) | 2024-12-01 |
| ES3008210T3 (en) | 2025-03-21 |
| SA522433282B1 (ar) | 2025-04-21 |
| AU2021209068B2 (en) | 2024-09-19 |
| WO2021146349A1 (en) | 2021-07-22 |
| JP7669048B2 (ja) | 2025-04-28 |
| US20230059010A1 (en) | 2023-02-23 |
| CN119432744A (zh) | 2025-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022013843A2 (pt) | Método de diferenciação de células neurais e composições relacionadas e métodos de uso | |
| Watson et al. | Macrophage inflammatory protein 2 inhibits β-amyloid peptide (1-42)-mediated hippocampal neuronal apoptosis through activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling pathways | |
| Zigmond et al. | Exercise: is it a neuroprotective and if so, how does it work? | |
| Yang et al. | BDNF and exercise enhance neuronal DNA repair by stimulating CREB-mediated production of apurinic/apyrimidinic endonuclease 1 | |
| Tsai et al. | Neuroprotective effects of betulin in pharmacological and transgenic Caenorhabditis elegans models of Parkinson’s disease | |
| Cao et al. | Changes in serum miRNA-let-7 level in children with attention deficit hyperactivity disorder treated by repetitive transcranial magnetic stimulation or atomoxetine: An exploratory trial | |
| BR112014010776A8 (pt) | neurônios dopaminérgicos (da) mesencefálicos para enxerto | |
| Boomkamp et al. | E pac and the high affinity rolipram binding conformer of PDE 4 modulate neurite outgrowth and myelination using an in vitro spinal cord injury model | |
| WO2016210372A3 (en) | Methods to treat neurological diseases | |
| Kawashiri et al. | Dimethyl fumarate ameliorates chemotherapy agent-induced neurotoxicity in vitro | |
| US8114892B2 (en) | Methods and compositions for the treatment of Parkinson's Disease | |
| Calkins et al. | Assessment of newly synthesized mitochondrial DNA using BrdU labeling in primary neurons from Alzheimer's disease mice: Implications for impaired mitochondrial biogenesis and synaptic damage | |
| Nesti et al. | Human dental pulp stem cells protect mouse dopaminergic neurons against MPP+ or rotenone | |
| MX2024001818A (es) | Composicion cannabinoide y aplicacion de la misma en la preparacion de farmacos para el tratamiento de enfermedades neurodegenerativas tales como la enfermedad de parkinson y la enfermedad de alzheimer. | |
| Mahmood et al. | Down-regulation of Nogo-A by collagen scaffolds impregnated with bone marrow stromal cell treatment after traumatic brain injury promotes axonal regeneration in rats | |
| Shadrina et al. | Comparison of the temporary dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax action | |
| Zhou et al. | Neuroprotective effect of angiotensin-(1–7) against rotenone-induced oxidative damage in CATH. a neurons | |
| Yuan et al. | Effect of nigranoic acid on Ca2+ influx and its downstream signal mechanism in NGF-differentiated PC12 cells | |
| BR112023003167A2 (pt) | Composições e métodos para doenças neurológicas | |
| EP4678236A3 (en) | C-terminal cdnf and manf fragments, pharmaceutical compositions comprising same and uses thereof | |
| Joshi et al. | Cell non-autonomous functions of homeoproteins in neuroprotection in the brain | |
| Andrews et al. | Alterations of p75 neurotrophin receptor and Myelin transcription factor 1 in the hippocampus of perinatal phencyclidine treated rats | |
| CN109498619A (zh) | 一种化合物在制备用于治疗和/或预防细菌性疾病的药物中的用途 | |
| Ravagnani et al. | Omics profile of iPSC-derived astrocytes from Progressive Supranuclear Palsy (PSP) patients | |
| WO2021099966A3 (en) | Novel benzothiophene derivatives and use thereof for stimulating mitochondrial turnover |